Canadians know of the benefits from medical treatments with cannabis, but still want confirmation from their doctors, according to a new survey made public on Tuesday (February 26).
The poll commissioned by Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF), a life science cannabis firm, found two in three Canadians are willing to use pharmaceutical drugs with cannabis if prescribed by a doctor.
However, this optimism goes down if the cannabis-based medicine were to not be covered by a public or private insurance.
The study results showed only four in 10 of respondents would still be interested in securing pharmaceutical products with cannabis if these were not covered.
Steeve Neron, senior vice president of marketing and medical affairs with Tetra Bio-Pharma, told the Investing News Network (INN) the study was conducted to take a snapshot of how receptive Canadian patients are to cannabis in pharmaceuticals.
Neron explained data from clinical trials will open the doors to the adoption of medicine with cannabis elements.
When asked if a similar study could be run with bigger parameters covering more Canadians, Neron the company is exploring the option but it would be a costly endeavour.
The results, from the just over 2,000 people polled, also found Canadians are unsure their doctor is “up-to-date on cannabis treatments.”
Tetra Bio-Pharma projects further improvement to treatments thanks to clinical trials in the space will help establish a trust for cannabis therapies with the medical community at large.
“Treatment with cannabis is complex, which is why the pharmaceutical pathway [ensure] precise dosing and consistent formulation,” Guy Chamberland, CEO of the company, said in a press release.
Last year, GW Pharmaceuticals provided a landmark moment for the medical cannabis space after its drug candidate, epidiolex, was approved by the US Food and Drug Administration (FDA).
This CBD-based medicine is designed to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two-years-old and older.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).